Brief Description
This competitive program is designed to support interventional Investigator Sponsored Research aimed at generating clinical evidence for atirmociclib in combination approaches in HR+/HER2- metastatic breast cancer (mBC) and/or HER2+ breast cancer. This RFP has two phases: Phase 1 requires applicants to submit a Concept application. Selected Concepts will then be invited to Phase 2, where applicants submit a full proposal for review.